Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure

Noordaa, M.E.M. van der; Duijnhoven, Frederieke van; Straver, Marieke E.; Groen, Emma J.; Stokkel, Marcel P. M.; Loo, Claudette E.; Elkhuizen, Paula H.M.; Russell, Nicola S.; Peeters, Marie‐Jeanne T. F. D. Vrancken

doi:10.1245/s10434-018-6404-y

Cited by 61 publications

(30 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, advancements of imaging have made physical examination an indispensable component of accurate response evaluation that includes modalities such as two-dimensional and three-dimensional mammography ultrasound, magnetic resonance imaging, nuclear medicine techniques (positron emission tomography, PET), fusion techniques (PET-CT, PET-MRI), as well as others (eg, optical imaging). [23][24][25][26]…”

Section: Introductionmentioning

confidence: 99%

<p>Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer</p>

Wang¹,

Mao²

2020

DDDT

142

View full text Add to dashboard Cite

Neoadjuvant chemotherapy is increasingly used in breast cancer, especially for downstaging the primary tumor in the breast and the metastatic axillary lymph node. Accurate evaluations of the response to neoadjuvant chemotherapy provide important information on the impact of systemic therapies on breast cancer biology, prognosis, and guidance for further therapy. Moreover, pathologic complete response is a validated and valuable surrogate prognostic factor of survival after therapy. Evaluations of neoadjuvant chemotherapy response are very important in clinical work and basic research. In this review, we will elaborate on evaluations of the efficacy of neoadjuvant chemotherapy in breast cancer and provide a clinical evaluation procedure for neoadjuvant chemotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer</p>

Wang¹,

Mao²

2020

DDDT

142

View full text Add to dashboard Cite

show abstract

“…According to the results, most of the patients received direct locoregional radiotherapy without ALND. Subsequently, the authors reported an 82% reduction of ALND for node-positive breast cancer patients (52).…”

Section: Imaging the Lymph-node Metastasesmentioning

confidence: 99%

Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer

Ming

Qian

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Breast cancer is a major disease with high morbidity and mortality in women worldwide. Increased use of imaging biomarkers has been shown to add more information with clinical utility in the detection and evaluation of breast cancer. To date, numerous studies related to PET-based imaging in breast cancer have been published. Here, we review available studies on the clinical utility of different PET-based molecular imaging methods in breast cancer diagnosis, staging, distant-metastasis detection, therapeutic and prognostic prediction, and evaluation of therapeutic responses. For primary breast cancer, PET/MRI performed similarly to MRI but better than PET/CT. PET/CT and PET/MRI both have higher sensitivity than MRI in the detection of axillary and extra-axillary nodal metastases. For distant metastases, PET/CT has better performance in the detection of lung metastasis, while PET/MRI performs better in the liver and bone. Additionally, PET/CT is superior in terms of monitoring local recurrence. The progress in novel radiotracers and PET radiomics presents opportunities to reclassify tumors by combining their fine anatomical features with molecular characteristics and develop a beneficial pathway from bench to bedside to predict the treatment response and prognosis of breast cancer. However, further investigation is still needed before application of these modalities in clinical practice. In conclusion, PET-based imaging is not suitable for early-stage breast cancer, but it adds value in identifying regional nodal disease and distant metastases as an adjuvant to standard diagnostic imaging. Recent advances in imaging techniques would further widen the comprehensive and convergent applications of PET approaches in the clinical management of breast cancer.

show abstract

“…The improvement in survival is more likely to occur in triple negative breast cancer, and in human epidermal growth factor 2 (HER2)-positive breast cancer, particularly when trastuzumab is added to the treatment regimen. The patients who achieve axillary pCR, show better loco-regional and survival outcomes, irrespective of the primary tumor response [45710111213141516]. NAT also provides adequate time for genetic testing, and planning for breast reconstruction, when indicated.…”

mentioning

confidence: 99%

“…In terms of prognosis, the response of the axillary nodes to NAT is known to be a more important factor, than the initial axillary status. The false-negative rates (FNRs) of SLNB after NAT range from 5% to 30%, but these FNRs can be reduced to less than 10% when the dual technique for SLN localization is used, and when more than two LNs can be dissected and examined [68101118192021].…”

mentioning

confidence: 99%

“…The rates for axillary pCR are higher, reaching up to 37% (between 5% and 75%). This rate reaches up to 21% in patients with estrogen receptor-positive/HER2-negative tumors, 60% in triple negative tumors, between 67% and 73% in HER2-positive tumors when trastuzumab is used in combination with chemotherapy, and up to 97% when dual HER2 blockage is applied [7810111516202324].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Neoadjuvant Therapy Should Be the Standard of Care for Every Node Positive Breast Cancer Patient

Hamdy

2019

J Breast Cancer

View full text Add to dashboard Cite

Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure

Abstract: Combining pre-NST axillary staging with PET/CT and post-NST staging with the MARI procedure resulted in an 82% reduction of ALNDs for cN + breast cancer patients.

Cited by 61 publications

References 42 publications

<p>Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer</p>

<p>Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer</p>

Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer

Neoadjuvant Therapy Should Be the Standard of Care for Every Node Positive Breast Cancer Patient

Contact Info

Product

Resources

About